Cervical cancer PD-L1 testing for KEYTRUDA^® (pembrolizumab)

Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]

PDF, 1.83 MB

KEYTRUDA in combination with chemotherapy, with or without bevacizumab, is indicated for the treatment of persistent, recurrent or metastatic cervical cancer in adults whose tumours express PD‑L1 CPS ≥1.

CPS = Combined Positive Score; PD-L1 = Programmed Death Ligand 1

More information about KEYTRUDA® (pembrolizumab) in cervical cancer

Supporting documentation

Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) 
By clicking the links above you will leave the MSD Connect website and be taken to the emc PI portal website